Beyond analysts' top -and-bottom-line estimates for Biogen (BIIB), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ...

Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...

Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from ...

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

An international clinical trial aimed at preventing Alzheimer’s disease (AD) in young adults who are at risk of developing ...

Addressing a preliminary injunction in patent litigation related to the Biologics Price Competition and Innovation Act (BPCIA), the US Court ...

The European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for BAT2506 as a biosimilar to reference p ...

Bain Capital has agreed to acquire Mitsubishi Chemical Group's pharmaceutical business for more than $3 billion, a deal that would allow the Japanese company to focus on its key chemical businesses.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

CEO Haruo Naito highlighted a 9% year-on-year revenue increase to 601.2 billion yen, with a focus on the pharmaceutical business driving growth. Key contributors included LEQEMBI with a 28.1 billion ...